- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07565662
Intrathecal Dexmedetomidine and Acute Neuropathic Pain After Lower Limb Amputation (DEX-RCT)
Intrathecal Dexmedetomidine Reduces Acute Neuropathic Pain After Lower Limb Amputation: A Randomized Controlled Trial
This randomized controlled trial evaluated the effect of adding intrathecal dexmedetomidine (10 µg) to hyperbaric bupivacaine (11 mg) for spinal anesthesia in patients undergoing lower limb amputation. Thirty patients (ASA I-III) scheduled for elective supra- or infracondylar amputation were randomly allocated to two groups: Control Group (n=15) received hyperbaric bupivacaine 11 mg plus saline 0.9%, and Experimental Group (n=15) received hyperbaric bupivacaine 11 mg plus dexmedetomidine 10 µg. Primary outcomes were duration of motor and sensory neuraxial block and postoperative analgesia at 48 hours. As a prespecified exploratory secondary outcome, incidence of acute neuropathic pain was assessed using the DN4 screening tool at 48 hours. The study was conducted at the Hospital Regional de Alta Especialidad Dr. Juan Graham Casasús, Villahermosa, Tabasco, Mexico, from 30 September to 15 December 2025. Ethics approval was obtained from the Institutional Review Board (CEI/JGC/C02-25) prior to patient enrollment.
Studieoversigt
Status
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Tabasco
-
Villahermosa, Tabasco, Mexico, 86126
- Hospital Regional de Alta Especialidad Dr. Juan Graham Casasus
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Patients scheduled for elective supra- or infracondylar lower limb amputation
- Age 18 to 65 years
- ASA physical status I-III
- Acceptance of neuraxial anesthetic technique
Exclusion Criteria:
-
Patient refusal of anesthetic procedure
- Prolonged coagulation times
- Anatomical abnormalities of the spine
- ASA IV classification
- Atrioventricular block grade 2 or 3 without pacemaker
- Neurological deterioration (Glasgow score less than 8)
- Hemodynamic instability
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Control Group - Bupivacaine Alone
Patients in this arm received hyperbaric bupivacaine 0.5% 11 mg plus saline 0.9% 0.1 ml administered intrathecally via spinal injection at level L2-L3. Total volume: 2.3 ml. |
Hyperbaric bupivacaine 0.5% 11 mg plus saline 0.9% 0.1 ml administered intrathecally. Total volume 2.3 ml. |
|
Eksperimentel: Experimental Group - Bupivacaine plus Dexmedetomidine
Patients in this arm received hyperbaric bupivacaine 0.5% 11 mg plus dexmedetomidine 10 µg administered intrathecally via spinal injection at level L2-L3. Total volume: 2.3 ml. |
Hyperbaric bupivacaine 0.5% 11 mg plus dexmedetomidine 10 µg administered intrathecally. Total volume 2.3 ml. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion Requiring Analgesic Rescue
Tidsramme: 48 hours postoperatively
|
Proportion of patients requiring at least one analgesic rescue dose during the postoperative period. |
48 hours postoperatively
|
|
Duration of Motor Block
Tidsramme: 48 hours postoperatively
|
Duration of motor block assessed by modified Bromage scale (0-3, higher scores indicate greater motor block). Measured at multiple timepoints through 48 hours postoperatively. |
48 hours postoperatively
|
|
Duration of Sensory Block
Tidsramme: 48 hours postoperatively
|
Duration of sensory block assessed by Hollmen scale. Measured at multiple timepoints through 48 hours postoperatively. |
48 hours postoperatively
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of Acute Neuropathic Pain
Tidsramme: 48 hours postoperatively
|
Incidence of acute neuropathic pain assessed by DN4 screening tool (0-10, score ≥4 indicates neuropathic pain component). Reported as exploratory secondary outcome. |
48 hours postoperatively
|
|
Heart Rate
Tidsramme: 4 hours postoperatively
|
Heart rate measured in beats per minute during the first 4 hours post-block. |
4 hours postoperatively
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Gabriel López-Ramírez, PhD, Universidad Juárez Autónoma de Tabasco
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Smerte
- Neurologiske manifestationer
- Sygdomme i nervesystemet
- Postoperative komplikationer
- Patologiske processer
- Neuromuskulære sygdomme
- Sygdomme i det perifere nervesystem
- Neuroadfærdsmæssige manifestationer
- Perceptuelle forstyrrelser
- Smerter, postoperativ
- Patologiske tilstande, tegn og symptomer
- Tegn og symptomer
- Neuralgi
- Fantomlem
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Azoler
- Imidazoler
- Uorganiske kemikalier
- Klorforbindelser
- Natriumforbindelser
- Chlorider
- Hydrochlorsyre
- Dexmedetomidin
- Natriumchlorid
Andre undersøgelses-id-numre
- JI-PG348
- CEI/JGC/C02-25 (Anden identifikator: HRAE Dr. Juan Graham Casasus)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
De-identified individual participant data underlying the published results will be available from the corresponding author on reasonable request.
IPD-delingstidsramme
Data will be available beginning 3 months after article publication and ending 5 years after publication.
IPD-delingsadgangskriterier
De-identified individual participant data will be shared with researchers who provide a methodologically sound proposal, approved by the corresponding author, for the purpose of verifying the published results or conducting individual-participant-data meta-analysis. Requests should be directed to the corresponding author.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- ICF
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .